Literature DB >> 9336423

Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death.

K Wong1, D D Gladman, J Husted, J A Long, V T Farewell.   

Abstract

OBJECTIVE: To identify the causes of death and mortality risk in patients with psoriatic arthritis (PsA) who were being followed up at a single outpatient clinic in Toronto, Ontario, Canada.
METHODS: Patients enrolled in the PsA Clinic between 1978 and 1993 were compared with the general population of Ontario. Deaths were identified from the clinic database and through linkage with the provincial mortality database, and causes were confirmed by death certificates. A standardized mortality ratio (SMR) was computed, based on the assumption that patients lost to followup were alive at the end of the study.
RESULTS: Of the 428 patients with PsA (194 women and 234 men), 53 (26 women and 27 men) died. The 4 leading causes of death were diseases of the circulatory (36.2%) or respiratory (21.3%) system, malignant neoplasms (17.0%), and injuries/poisoning (14.9%). The SMR for the female cohort was 1.59, and for the men, it was 1.65, indicating a 59% and 65% increase in the death rate, respectively. Deaths due to respiratory causes were particularly increased in these patients.
CONCLUSION: The results suggest that this PsA Clinic outpatient population had an increased mortality risk.

Entities:  

Mesh:

Year:  1997        PMID: 9336423     DOI: 10.1002/art.1780401021

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  76 in total

1.  TNFalpha therapy in psoriatic arthritis and psoriasis.

Authors:  P Mease
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

Review 2.  The Epidemiology of Psoriatic Arthritis.

Authors:  Alexis Ogdie; Pamela Weiss
Journal:  Rheum Dis Clin North Am       Date:  2015-09-11       Impact factor: 2.670

3.  Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

Authors:  A Kavanaugh; G G Krueger; A Beutler; C Guzzo; B Zhou; L T Dooley; P J Mease; D D Gladman; K de Vlam; P P Geusens; C Birbara; D G Halter; C Antoni
Journal:  Ann Rheum Dis       Date:  2006-11-17       Impact factor: 19.103

Review 4.  Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology.

Authors:  Philip Mease
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

5.  Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity.

Authors:  Baris Yilmazer; Tayfun Sahin; Berrin Öztaş Unlu; Hale Maral Kir; Ayse Cefle
Journal:  Rheumatol Int       Date:  2015-02-11       Impact factor: 2.631

Review 6.  Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?

Authors:  Dafna D Gladman; Vinod Chandran
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.592

7.  Case report: Infliximab treatment in two Chinese patients with psoriatic arthritis.

Authors:  Xi Xie; Jin-wei Chen; Fen Li; Jing Tian; Jie-sheng Gao; David Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2010-10       Impact factor: 3.066

Review 8.  Update on the natural history and systemic treatment of psoriasis.

Authors:  Stephen K Richardson; Joel M Gelfand
Journal:  Adv Dermatol       Date:  2008

9.  Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate.

Authors:  J Gratacós; E Casado; J Real; J C Torre-Alonso
Journal:  Ann Rheum Dis       Date:  2006-12-19       Impact factor: 19.103

10.  Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study.

Authors:  Floranne C Wilson; Murat Icen; Cynthia S Crowson; Marian T McEvoy; Sherine E Gabriel; Hilal Maradit Kremers
Journal:  Arthritis Rheum       Date:  2009-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.